Micropapillary transitional cell carcinoma of the urinary bladder

López, José I.; Elorriaga, K; Imaz, I; Bilbao, Francisco José Larrea

doi:10.1111/j.1365-2559.1999.0696f.x

Cited by 22 publications

(22 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To date, there are only 45 cases of histologically diagnosed MPTCC in the literature. [1][2][3][4][5] Over an 11-year period, we found six cases in our hospital files; three of these patients had urine cytologies. The first and second patients had urine cytologies that showed micropapillary clusters of cells early after their clinical presentation.…”

Section: Discussionmentioning

confidence: 99%

Micropapillary Variant of Transitional Cell Carcinoma of the Urinary Bladder

Ylagan

Humphrey²

2001

Acta Cytologica

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Micropapillary Variant of Transitional Cell Carcinoma of the Urinary Bladder

Ylagan

Humphrey²

2001

Acta Cytologica

View full text Add to dashboard Cite

“…MPUC is a relatively rare subtype of urothelial carcinoma that comprises approximately 3,000 to 4,000 new cases diagnosed each year in the United States, an incidence just below that of the successfully targeted diseases including breast and lung cancers, melanoma, and hematologic malignancies such as chronic myelogenous leukemia (6)(7)(8)(9). MUPC is widely considered to have an adverse prognosis, a reflection of the propensity to invade lymphovascular spaces and spread to distant sites early in the course of the disease (6-9).…”

Section: Discussionmentioning

confidence: 99%

“…Encompassing approximately 5% of all bladder cancers, MPUC is a clinically important lesion characterized by a distinctive histology that features small micropapillae created by clusters of 4 to 5 cells across, peripherally situated nuclei, and cytoplasmic vacuoles with a strong tendency to develop intralymphatic permeation or simulate lymphovascular involvement because of the production of peritumoral stromal retraction artifacts (6)(7)(8)(9). It is well-accepted that the diagnosis of MPUC indicates an adverse prognosis and pathologists have strongly recommended that even if the minority of a urinary bladder urothelial carcinoma features a MPUC pattern, the diagnosis of MPUC should either be made outright or the tumor should be classified as urothelial carcinoma with MPUC features (6)(7)(8)(9). Among the noteworthy clinicopathologic features of MPUC is the association of metastatic disease at the time of diagnosis for a tumor with either no invasion or limited invasion of the bladder wall.…”

Section: Introductionmentioning

confidence: 99%

A High Frequency of Activating Extracellular Domain ERBB2 (HER2) Mutation in Micropapillary Urothelial Carcinoma

Ross

Wang

Al‐Rohil

et al. 2014

Clinical Cancer Research

124

View full text Add to dashboard Cite

Purpose: Micropapillary urothelial carcinoma (MPUC) is a rare and aggressive form of bladder cancer. We conducted genomic analyses [next-generation sequencing (NGS)] of MPUC and non-micropapillary urothelial bladder carcinomas (non-MPUC) to characterize the genomic landscape and identify targeted treatment options.Experimental Design: DNA was extracted from 40 mm of formalin-fixed paraffin-embedded sections from 15 MPUC and 64 non-MPUC tumors. Sequencing (NGS) was performed on hybridization-captured, adaptor ligation-based libraries to high coverage for 3,230 exons of 182 cancer-related genes plus 37 introns from 14 genes frequently rearranged in cancer. The results were evaluated for all classes of genomic alteration.Results: Mutations in the extracellular domain of ERBB2 were identified in 6 of 15 (40%) of MPUC: S310F (four cases), S310Y (one case), and R157W (one case). All six cases of MPUC with ERBB2 mutation were negative for ERBB2 amplification and Erbb2 overexpression. In contrast, 6 of 64 (9.4%) non-MPUC harbored an ERBB2 alteration, including base substitution (three cases), amplification (two cases), and gene fusion (one case), which is higher than the 2 of 159 (1.3%) protein-changing ERBB2 mutations reported for urinary tract cancer in COSMIC. The enrichment of ERBB2 alterations in MPUC compared with non-MPUC is significant both between this series (P < 0.0084) and for all types of urinary tract cancer in COSMIC (P < 0.001).Conclusions: NGS of MPUC revealed a high incidence of mutation in the extracellular domain of ERBB2, a gene for which there are five approved targeted therapies. NGS can identify genomic alteration, which inform treatment options for the majority of MPUC patients. Clin Cancer Res; 20(1); 68-75. Ó2013 AACR.

show abstract

“…Tras la descripción de Amin se han comunicado varios casos clínicos aislados 5-7 y pequeñas series de pacientes entre las que destacan la de Johansson 8 (20 casos), Samaratunga 9 (20 casos), Lopez 10 (8 casos) y Maranchie 11 (5 casos).…”

Section: Discussionunclassified

Carcinoma micropapilar de vejiga: aportación de un caso y revisión de la bibliografía

et al. 2005

View full text Add to dashboard Cite

micropapilar (CMP) es una variante anatomopatológica infrecuente de carcinoma vesical de comportamiento agresivo. Se presenta habitualmente como carcinoma de alto grado, en estadios avanzados y asociado a otras formas histológicas en proporciones variables. No manifiesta signos clínicos diferenciales con el carcinoma vesical típico. Los estudios de marcadores moleculares son todavía contradictorios. El tratamiento debería ser precoz y agresivo, fundamentalmente quirúr-gico, dado que la Radioterapia y la Quimioterapia han demostrado escasa eficacia hasta el momento.Presentamos el caso de un varón de 72 años con síntomas miccionales de larga evolución y hematuria macroscópica de reciente aparición que se diagnosticó de CMP en estadio avanzado. Al año de la cistectomía radical asociada a quimioterapia con carboplatino y gemcitabina se evidenció progresión rápida de la enfermedad y falleció a los 14 meses.Palabras clave: Vejiga. Carcinoma transicional. Carcinoma micropapilar. ABSTRACT MICROPAPILLARY CARCINOMA OF THE BLADDER: CASE REPORT AND REVIEWOF THE LITERATURE Micropapillary carcinoma is an uncommon pathologic variant of bladder carcinoma with aggressive behavior. Its usual presentation is like a high grade and high stage carcinoma and associated with other histologic types in different proportion. It doesn´t differ clinically from normal transitional cell carcinoma of the bladder. Studies of molecular markers are still contradictories. Treatment should be early and aggresive, based on surgical therapy as radiotherapy and chemotherapy have shown limited results.We report a 72 years old man suffering from low urinary tract symptoms for years and recently presented gross hematuria. He was diagnosed as high stage micropapillary carcinoma. One year after radical cystectomy and subsequent chemotherapy based on carboplatin and gemcitabine , progression of the disease was shown on CT and the patient died 14 months after the diagnosis.

show abstract

Micropapillary transitional cell carcinoma of the urinary bladder

Cited by 22 publications

References 2 publications

Micropapillary Variant of Transitional Cell Carcinoma of the Urinary Bladder

Micropapillary Variant of Transitional Cell Carcinoma of the Urinary Bladder

A High Frequency of Activating Extracellular Domain ERBB2 (HER2) Mutation in Micropapillary Urothelial Carcinoma

Carcinoma micropapilar de vejiga: aportación de un caso y revisión de la bibliografía

Contact Info

Product

Resources

About